At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Multicenter, Randomized Trial Comparing Tacrolimus/Sirolimus/Methotrexate Versus Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma
In Brief
A Phase 3 clinical trial evaluating Sirolimus, Methotrexate, and 3 other interventions for Non-hodgkin Lymphoma and Hodgkin Lymphoma. Completed, enrolled 139 participants across 5 sites.
Detailed Summary
This trial is comparing whether using a drug called sirolimus for graft versus host disease (GVHD) prevention can decrease the chance of the participant's lymphoma relapsing after transplantation, compared to using a standard GVHD prevention regimen without sirolimus. Since mTOR inhibitors have anti-lymphoma activity, their use after transplantation may lead to a decreased risk of relapse and hence better transplantation outcome.
Study Details
Timeline
Interventions
Taken orally for at least 12 months
Given intravenously on the first, third and sixth day after transplant
Taken orally or given intravenously for at least 6 months
Taken orally or given intravenously for at least 6 months
Taken orally for about 2 months